Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Fifth People's Hospital, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Key Laboratory of Smart Drug Delivery (MOE), School of Pharmacy, Fudan University, Shanghai, 201203, China.
Nat Commun. 2024 Aug 12;15(1):6892. doi: 10.1038/s41467-024-51066-6.
Nipah virus infection, one of the top priority diseases recognized by the World Health Organization, underscores the urgent need to develop effective countermeasures against potential epidemics and pandemics. Here, we identify a fully human single-domain antibody that targets a highly conserved cryptic epitope situated at the dimeric interface of the Nipah virus G protein (receptor binding protein, RBP), as elucidated through structures by high-resolution cryo-electron microscopy (cryo-EM). This unique binding mode disrupts the tetramerization of the G protein, consequently obstructing the activation of the F protein and inhibiting viral membrane fusion. Furthermore, our investigations reveal that this compact antibody displays enhanced permeability across the blood-brain barrier (BBB) and demonstrates superior efficacy in eliminating pseudovirus within the brain in a murine model of Nipah virus infection, particularly compared to the well-characterized antibody m102.4 in an IgG1 format. Consequently, this single-domain antibody holds promise as a therapeutic candidate to prevent Nipah virus infections and has potential implications for vaccine development.
尼帕病毒感染是世界卫生组织认定的重点疾病之一,突显了开发针对潜在疫情和大流行的有效对策的紧迫性。在这里,我们通过高分辨率冷冻电镜(cryo-EM)结构阐明,鉴定了一种针对尼帕病毒 G 蛋白(受体结合蛋白,RBP)二聚体界面上高度保守的隐蔽表位的完全人源单域抗体。这种独特的结合模式破坏了 G 蛋白的四聚化,从而阻止了 F 蛋白的激活并抑制了病毒膜融合。此外,我们的研究表明,这种紧凑的抗体具有增强的血脑屏障(BBB)通透性,并在尼帕病毒感染的小鼠模型中显示出在大脑中消除假病毒的优异效果,特别是与 IgG1 形式的特征明确的 m102.4 抗体相比。因此,这种单域抗体有望成为预防尼帕病毒感染的治疗候选药物,并有可能对疫苗开发产生影响。